RBC Capital initiated coverage of 4D Molecular with an Outperform rating and $25 price target. The shares trading close to cash “creates an attractive buying opportunity” given the company’s differentiated platform tailoring gene therapy to specific tissue, the analyst tells investors in a research note. The firm says 4D has posted “impressive” initial data for wet age-related macular degeneration with an ideal route of administration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FDMT:
- 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
- Cantor starts 4D Molecular at Overweight on ‘compelling’ risk/reward
- 4D Molecular initiated with an Overweight at Cantor Fitzgerald
- 4D Molecular receives EMA PRIME designation for 4D-150
- 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
